| URL | https://www.reuters.com/business/healthcare-pharma |
| Source | Reuters |
| Date Published | 12/03/2025 |
| Author Name | Kamal Choudhury |
| Company/Division name | Excelsior Sciences |
| Parent company | Excelsior Sciences |
| Reshoring category: | Reshoring |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 95 |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | small molecules |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Manufacturing/engineering joint innovation (R&D) |
| Government Incentive dollar amount: | 25,000,000 |